Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Upcoming Trial
View:
Post by Nitrodouglas on Oct 02, 2024 11:52am

Upcoming Trial

Mr. Hopton got back to me, clarified that the upcoming trial would be 3 months. He said it will be a cheaper trial this go around and that they are adding features which will add value. I'm assuming this is the new formulation. He also said that they will be collecting data at several intervals.

He confirmed the early 2025 launch window and will endeavour to keep us updated!
Comment by Pandora on Oct 02, 2024 5:32pm
I assume you did not take the opportunity to ask him how the Allergan agreement got screwed up and when, if ever, it may be straightened out?
Comment by tylerreddick on Oct 02, 2024 6:03pm
Thanks for sharing.  I assume there was no indication when the trial would start? Encouraging that he is sticking with the "early" 2025 launch. That would place it sometime in the first 3 months or so, which means that long suffering shareholders have just a short few months before that very material event. With the financing announcement coming "shortly", the trial ...more  
Comment by MirrorWorldMan on Oct 03, 2024 11:44am
If Howie had an ounce of foresight he would talk to any of these interested potential partners design the trial around what they want to see in the results. This includes any current comparators.  Then he would announce the design if the trial, saying that these are the endpoints that other companies wanted to see.  what a klutz
Comment by LakeOromocto on Oct 03, 2024 5:40pm
Howie did drsign the last trial with input from Abbvie/allergan. Dont always assume the worst. Trust me he is getting lots of input into this latest trial. GLTA
Comment by Pandora on Oct 03, 2024 6:50pm
We (at least speaking for myself) cannot afford another outcome like we got from Allergan/Abbvie. Two times nothing still equals nothing. (Maybe there were a few bucks passed hands along the way but we as shareholders certainly did not see it). If that outcome was administered on our side by Howie then I think we need a new person on negotiations for our side. First quarter of 2025? I guess ...more  
Comment by Pandora on Oct 03, 2024 6:54pm
Didn't really say it but I'm assuming the "trial" will take us into 2025 and then based on what kind of results we get some period of negotiations with various market players will take place -- no idea how long that might take??
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities